New Treatment to Prevent Skin Inflammation and atopic dermatisis - Techno Market

Offre n°2407
New Treatment to Prevent Skin Inflammation and atopic dermatisis

L'innovation

The invention refers to novel tocotrienol derivatives that specifically inhibit 5-lipoxygenase (5-LOX) activity and leukotrienes synthesis. Leukotrienes promote inflammation. Novel tocotrienol derivatives strongly inhibit 5-LOX activity at very low concentrations (nanomolar levels) thus preventing leukotrienes synthesis and inflammation.

A screening step has revealed many secondary metabolites isolated from Garcinia amplexicaulis and Garcinia kola as potential anti-inflammatory agents. In vitro tests highlighted 2 hits : garcinoïc acid and α-amplexichromanol. As a consequence, additional tests were realized on an atopic dermatitis Reconstructed Human Epidermis model (RHE) by SYNELVIA in Toulouse : α-amplexichromanol proved to prevent atopic dermatitis. Its anti-inflammatory activity is close to that of dexamethasone, a strong dermocorticoid with huge side-effects.

Reactive/sensitive skin and atopic dermatitis are major hurdles in the field of dermo-cosmetology and represent huge markets. Many companies are looking for innovative technologies and natural ingredients to prevent skin inflammation. Tocotrienol derivatives proved to be efficient molecules targeting inflammation. RHE in vitro tests confirmed their ability to prevent inflammation and atopic dermatitis. Moreover raw materials sourcing are clearly identified and processes are easy to scale-up.

Ses bénéfices

  • Hemisynthetic derivatives
  • No toxicity below 50 µm (RHE model)
  • SYNELVIA’s objectivization report : “effective for the treatment of atopic dermatitis” (details available on demand), anti-inflammatory activity close to that of dexamethasone, a strong dermocorticoid with huge side-effects

Ses applications

  • Dermo-cosmetic applications : skin inflammation and atopic dermatitis
Intéressé par cette offre ?
Contactez Hervé LE DEIT
Télécharger PDF Favoris

Stade de développement

  • IN VITRO

Laboratoire de recherche

EA 921 - SONAS

Équipe de recherche

SUBSTANCES D'ORIGINALE NATURELLE ET ANALOGUES STRUCTURAUX

Propriété intellectuelle associée

EP : EP15182827 - filed on the 08-27-2015
WO - CA,CN,EP,JP,US

Créer une notification

Recevez les prochaines offres qui correspondent à vos besoins.
Merci pour l’intérêt que vous portez aux innovations proposées par la SATT Ouest Valorisation.
Nous ne manquerons pas de vous informer, par email, des futures innovations correspondant à votre besoin.
Pour toute autre demande, faites votre demande ICI.